Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians
Publicaciones Similares
![Guía Dislipemias 2016](http://sadeno.es/wp-content/uploads/2022/02/photo-1529119368496-2dfda6ec2804-768x768-2-landscape.jpg)
Guía Dislipemias 2016
Descárgate aquí la Guía Dislipemias 2016
Artículo Diamond Study Group
Está disponible para descarga el artículo Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 1 Diabetes Using Insulin Injections. Autores: RoyW. Beck, MD, PhD; Tonya Riddlesworth, PhD; Katrina Ruedy, MSPH; Andrew Ahmann, MD; Richard Bergenstal, MD; Stacie Haller, RD, LD, CDE; Craig Kollman, PhD; Davida Kruger, MSN, APN-BC; Janet B….
Artículo Monitorización Glod
Ya está disponible para su consulta el artículo Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections. The GOLD Randomized Clinical Trial Descárgalo aquí
Evidencias de los nuevos tratamientos para el colesterol
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular disease. How much one should or safely can lower this risk factor remains debated. We aimed to explore the relationship between progressively lower…
Artículo Tiroides y embarazo y posparto
Está disponible para descarga el artículo sobre Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum, de la Asociación Americana de Tiroides. Descárgalo aquí
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial
Consulta aquí el artículo: Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial